Assessing the Impact: New Data in T790+ NSCLC

Slides:

Advertisements

Similar presentations

Personalized medicine in lung cancer R4 김승민. Personalized Medicine in Lung Cancer patients with specific types and stages of cancer should be treated.

Advertisements

N Engl J Med; Volume 373(17): ; October 22, 2015

BLOOM: Osimertinib Shows Promising Activity in Patients With EGFRm+ Advanced NSCLC and Leptomeningeal Metastases CCO Independent Conference Coverage* of.

Case: EGFR mutation (+) NSCLC c CNS only progression

Rosell R et al. Proc ASCO 2011;Abstract 7503.

This program will include a discussion of off-label treatment and investigational agents not approved by the FDA for use in the US, and data that were.

Patient Case 1 Patient Case 1: PET/CT Scan.

A New Path Forward: Immune Checkpoint Inhibitors in Bladder Cancer

Crystal digital PCR for detection and quantification of circulating EGFR mutations in advanced non-small cell lung cancer Cécile Jovelet Postdocoral fellow.

Strategies for the Management of EGFR TKI Resistance in Advanced NSCLC

Steps to Optimizing Outcomes in Patients With Advanced Prostate Cancer

Clinical Considerations in the Management of EGFR-Mutated Advanced NSCLC.

Perspectives on Triple-Negative Breast Cancer

The New Taxonomy of Metastatic NSCLC and Physician Treatment Based on Pathologic and Molecular Characteristics The New Taxonomy of Metastatic Non-Small.

Fundamental Concepts in the Diagnosis of Advanced NSCLC

New Patient Journeys in Non-small cell lung cancer

Progression After Cancer Immunotherapy in Advanced NSCLC

The Nurse View: Best Practices in Advanced Non-Small Cell Lung Cancer

Updates in Lung Cancer: Insights From Vienna

Proof-of-concept clinical studies validating AZD9291 as a mutant-selective EGFR kinase T790M inhibitor. Proof-of-concept clinical studies validating AZD9291.

Updates and Perspectives on Third-Generation EFGR TKIs in Advanced NSCLC.

Introduction. For Pulmonologists by Pulmonologists: Diagnosis of NSCLC in an Age of Biomarkers.

Aligning Patients and Clinicians: Optimizing Outcomes in Metastatic NSCLC.

THE CONTINUUM OF CARE IN mCRC: OPTIMIZING USE OF EGFR ANTIBODIES

T790M Mutation-Positive NSCLC: A Multidisciplinary Case Conference

EGFR Inhibitors in Advanced NSCLC: Who, When, and Why?

Optimizing Targeted Therapy for HER2-Positive Advanced Breast Cancer: First-line Considerations.

Advanced Lung Cancers: What's on the Horizon?

Moving Care Forward in Advanced NSCLC

EGFR-Mutated NSCLC and CNS Involvement: the Conundrum

When Is Biologic Therapy Appropriate for HS?

Oncologia Polmonare – AOU S. Luigi Gonzaga, Orbassano (To)

Immune Checkpoint Inhibitors in Lung Cancer

Noemi Reguart Hospital Clínic de Barcelona

University of British Columbia British Columbia Cancer Agency

The Road to Quality Improvement in HER2-Positive Breast Cancer

Locally Advanced Lung Cancer

Putting Evidence Into Practice: Highlights From Toronto

Defining Patient-Centered Care: Spotlight on Advanced Non-Small Cell Lung Cancer.

Optimizing Targeted Therapy for HER2-Positive Advanced Breast Cancer: Considerations for Previously Treated Disease.

Moving the Goal Post: Multidisciplinary Management of Advanced NSCLC

Patient-Centered Management in Advanced Non-Small Cell Lung Cancer

All for One: Multidisciplinary Management in EGFR-Mutated NSCLC

Practical Guidance on the Management of Pan-Negative NSCLC

Meta-Analysis of First-Line Therapies in Advanced Non–Small-Cell Lung Cancer Harboring EGFR-Activating Mutations Benjamin Haaland, PhD, Pui San Tan,

Practical Strategies to Guideline-Recommended Biomarker Testing in NSCLC.

This program will include a discussion of off-label treatment and investigational agents not approved by the Food and Drug Administration for use in the.

This program will include a discussion of off-label treatment and investigational agents not approved by the FDA for use in the United States, and data.

From Adjuvant to Metastatic in Melanoma

Multidisciplinary Management in Non-Small Cell Lung Cancer (NSCLC)

Optimizing Characterization of NSCLC Through Specialty Collaboration

The Nurse View: Spotlight on Immune Checkpoint Inhibitors in Advanced Lung Cancer.

THE CONTINUUM OF CARE IN mCRC: OPTIMIZING USE OF EGFR ANTIBODIES

Quality Improvement and Molecular Profiling in Advanced Non-Small Cell Lung Cancer.

Educational Objectives

Checkpoint Inhibitors in First-Line Advanced NSCLC

Third-Generation EGFR TKIs

Compound Uncommon EGFR Mutations in a Patient with Advanced NSCLC and Durable Response to Sequential EGFR Targeted Therapies Mary Linton B Peters, MD,

The Nurse View: Spotlight on EGFR-Mutated NSCLC

Finding the Right Sequence in Patients With EGFR-Mutated NSCLC

Physiologic vs Chronologic Age

Clinical Pearls in the Management of Patients With Advanced Non-Small Cell Lung Cancer.

New Options for the Treatment of Hepatocellular Carcinoma

What's on the Horizon in the Management of EGFR-Mutated Lung Cancer?

Detection of somatic mutations in plasma allows for non-invasive real time therapy response monitoring of lung cancer patients José Carlos Machado.

Next-Generation Sequencing and ctDNA

Immune Checkpoint Inhibitors in Lung Cancer

Physiologic vs Chronologic Age

Updates in Best Practices in Non-Small Cell Lung Cancer

Presentation transcript:

Assessing the Impact: New Data in T790+ NSCLC

Lung Cancer Leading Cause of Cancer-Related Mortality Worldwide

Frequency of Genomic Alterations in NSCLC

Treatment of Patients With Newly Diagnosed Advanced EGFR+ NSCLC

Case Initial Presentation and Treatment

Considerations for Treatment at Progression

NSCLC: Progressive Disease

Rebiopsy at Time of Progression When and How?

Plasma Biopsy

Plasma Testing vs Tissue Testing A Tale of 2 Imperfect Tests

Case (cont) Disease Progression: What Are Her Options?

Erlotinib Until and Beyond Progression in Asian Patients With EGFR+ NSCLC ASPIRATION Study

Gefitinib + Chemotherapy After Progression on Gefitinib IMPRESS Study

Case (cont) Started On Osimertinib

AURA3: Osimertinib or Platinum-Pemetrexed in EGFR T790M-Positive Lung Cancer Osimertinib Superior To Chemotherapy

AURA3 Results Patients With CNS Metastases

Osimertinib: Intracranial Response Rate in CNS Metastases Results From a Pooled Analysis

Osimertinib in Leptomeningeal Disease Preliminary Results of the BLOOM Study

Osimertinib as Front-Line Treatment in EGFR+ NSCLC Results From AURA Study

Questions About T790M in the Treatment-Naive Patient

Osimertinib: First-line EGFR MT Study: FLAURA

Other Third-Generation EGFR TKIs in Development for Front-Line Therapy in NSCLC

Concluding Remarks

Abbreviations

Abbreviations (cont)